Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
Rhea-AI Summary
Protagonist Therapeutics (NASDAQ:PTGX) announced that Dinesh V. Patel, Ph.D., President and CEO will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 8:15 AM PST.
The company will hold one-on-one investor meetings during the conference. A live webcast is available at the provided J.P. Morgan link, and a replay will be posted on Protagonist's Investor Relations Events and Presentations webpage for one year following the event. Investors seeking meetings should contact their J.P. Morgan representative.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, PTGX gained 0.09%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PTGX was down 2.27% while close peers showed mixed moves: MIRM up 1.84%, AAPG down 3.24%, AKRO slightly up 0.24%, MTSR down 0.34%, and ZLAB down 1.14%. Momentum scanner only flagged CRNX up 4.64% without news, pointing to stock-specific rather than broad sector dynamics.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 05 | NDA submission | Positive | -3.4% | NDA filed for rusfertide in PV with positive VERIFY Phase 3 data. |
| Nov 06 | Earnings & update | Positive | -0.3% | Q3 2025 results and broad pipeline milestones with strong cash runway. |
| Nov 03 | Conference data | Positive | +0.7% | Multiple rusfertide presentations at ASH highlighting Phase 3 and extension data. |
| Oct 27 | Clinical data | Positive | +0.5% | New icotrokinra data in UC and psoriasis supporting ongoing ICONIC programs. |
| Oct 07 | Clinical data | Positive | +2.1% | Phase 2b ANTHEM-UC results showing strong efficacy and favorable safety. |
Recent fundamentally positive updates (NDA filings, strong trial data, solid cash) have sometimes seen muted or negative next-day price reactions.
Over the past few months, Protagonist reported multiple key milestones, including new icotrokinra ulcerative colitis data on Oct 7, 2025 and broader psoriasis/UC results on Oct 27, 2025, both with favorable efficacy and safety signals. Rusfertide data were showcased at ASH in early December per the Nov 3, 2025 announcement, leading into a full NDA submission on Jan 5, 2026. Today’s J.P. Morgan conference participation fits into this ongoing investor and partner visibility campaign rather than introducing new clinical or regulatory data.
Regulatory & Risk Context
The company has an effective S-3ASR shelf registration dated 2025-08-06 with no reported usage to date, indicating capacity for future registered offerings if the company chooses to access capital markets.
Market Pulse Summary
This announcement highlights Protagonist’s participation in the 44th Annual J.P. Morgan Healthcare Conference, with a scheduled presentation on January 13, 2026 and a webcast available for one year. In the months leading up to this, the company reported positive clinical data and an NDA submission for rusfertide. Investors evaluating this event alongside the effective S-3ASR, insider selling activity, and prior regulatory milestones may focus on updates to the pipeline narrative and partnering strategy during the presentation.
AI-generated analysis. Not financial advice.
NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference taking place January 12-15, 2026 in San Francisco, CA. The Company will also participate in one-on-one meetings.
44th Annual J.P. Morgan Healthcare Conference - January 12-15, 2026
Format: Company Presentation
Day/Time: Tuesday, January 13 at 8:15 AM PST
If you are interested in meeting with the Protagonist team during the conference, please reach out to your J.P. Morgan representative.
A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage for one year following the event.
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with a New Drug Application (NDA) for icotrokinra submitted to the FDA in July, and an NDA for rusfertide submitted in December 2025. Icotrokinra (formerly, JNJ-2113), is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R"), which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra's joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for the development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and the oral hepcidin program.
More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company's website at https://www.protagonist-inc.com.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
Media Contact
Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
SOURCE: Protagonist Therapeutics
View the original press release on ACCESS Newswire
FAQ
When will Protagonist Therapeutics (PTGX) present at the 2026 J.P. Morgan Healthcare Conference?
Who from Protagonist Therapeutics (PTGX) is presenting at JPM 2026?
How can investors watch the Protagonist Therapeutics (PTGX) presentation webcast?
Can shareholders request a one-on-one meeting with Protagonist Therapeutics (PTGX) at JPM 2026?
Where will the replay of the Protagonist Therapeutics (PTGX) JPM presentation be available?
